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Abstract
Background: Autism spectrum disorder (ASD) is a neurodevelopmental disease which affects 1 in 88 children.
Its etiology remains basically unknown, but it is apparent that neuroinflammation is involved in disease
development. Great attention has been focused on pro-inflammatory cytokines, and several studies have reported their
dysfunction unbalance in serum as well as in the brain. The present work aimed at evaluating putative dysregulation of
interleukin-18 (IL-18), a pro-inflammatory cytokine of the IL-1 family in the sera of patients with ASD of different grades,
compared to healthy controls, as well as in postmortem brain samples obtained from patients with tuberous sclerosis
as well as acute inflammatory diseases. Moreover, quantitative analysis of IL-18 was performed in the sera and brain
obtained from Reeler mice, an experimental model of autism.
Methods: Serum IL-18 levels were measured by ELISA. IL-18 was localized by immunohistochemical analysis in brain
sections obtained from tuberous sclerosis and encephalitis patients, as well as from gender- and age-matched
controls, and in the brain sections of both Reeler and wild-type mice. IL-18 was also quantified by Western
blots in homogenates of Reeler and wild-type mice brains. IL-18 binding protein (IL-18BP) was evaluated in
Reeler and wild-type mice plasma as well as in their brains (sections and homogenates).
Results: IL-18 content decreased in the sera of patients with autism compared to healthy subjects and in
Reeler sera compared to wild-type controls. IL-18 was detected within glial cells and neurons in the brain of
subjects affected by tuberous sclerosis and encephalitis whereas in healthy subjects, only a weak IL-18 positivity was
detected at the level of glial cells. Western blot identified higher amounts of IL-18 in Reeler brain homogenates
compared to wild-type littermates. IL-18BP was expressed in higher amounts in Reeler brain compared to the brain of
wild-type mice, whereas no significant difference was detected comparing IL-18BP plasma levels.
Conclusions: IL-18 is dysregulated in ASD patients. Further studies seemed necessary to clarify the molecular details
behind IL-18 increase in the brain and IL-18 decrease in the sera of patients. An increase in the size of the patient
cohort seems necessary to ascertain whether decreased IL-18 content in the sera can become a predictive biomarker
of ASD and whether its measure, in combination with other markers (e.g., increased levels of brain-derived
neurotrophic factor (BDNF)), may be included in a diagnostic panel.
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Background
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder characterized by repetitive and stereotypic behav-
iors and impairment in social communications. In most
cases, ASD is clinically diagnosed during the first 3 years
of age and is a lifelong condition for most [1]. The inci-
dence of autism has dramatically increased in recent de-
cades rising from 2–5/10,000 children to 60–100/10,000
[2]. One out of 88 children has been identified with ASD,
which marks a 78 % increase since the first report in
2007. A recent systematic review established that evi-
dence for a pro-inflammatory state is stronger for autism
spectrum disorders compared to other children and ado-
lescent neuropsychiatric disorders [3]. The etiology of
autism is practically still unknown although numerous
studies have identified a number of genes and environ-
mental factors related to the development of the disease.
Alternatively, the involvement of chronic neuroinflamma-
tion has been ascertained [4–7]. Here, dysregulated im-
mune mediators act by altering the normal development
of the nervous system leading in particular to the up-
regulation of inflammatory cytokines in the ASD brain,
probably due to altered blood–brain barrier functions
[4]. Cytokines have been reported to influence the de-
velopment of neuronal and glial cells as well as behavioral
phenotypes. A bulk of studies showed that multiple mem-
bers of the large family of cytokines are essential for
proper brain development and for synaptic plasticity and
responses to injury [5]. Cytokines are produced by neu-
rons, astrocytes as well as microglia, and abnormalities in
their levels were reported in association with neurodeve-
lopmental disorders. Interleukin (IL)-6 elevation in the
brain, dependent on glia activation, was related to im-
paired neuroanatomical structures and altered synaptic
plasticity. Some cytokines like IL-1β and tumor necrosis
factor-α (TNF-α) induce neurotoxicity through elevated
glutamate production that results in neuronal excitotoxic
death [8]. In a previous study, we showed that cytokines
IL-1β, IL-6, IL-12, TNF-α, and IL-23 were significantly
increased in the blood serum of ASD patients [9]. The
chronic alterations in the inflammatory and immuno-
logical responses in patients with autism suggest that this
can constitute an endophenotype for ASD. Peripheral
cytokines are known to affect different behaviors in-
cluding sickness and depression and are increased in
the brain of subjects with Alzheimer’s disease [10, 11].
Since both the neuroinflammatory processes and the
increased immune response observed in ASD would com-
prise high levels of cytokines in the brain, these proteins
could affect behavior [12].
Our interest focuses in the present paper on IL-18, a
member of the IL-1 family of cytokines, synthesized as an
inactive precursor requiring processing by caspase-1 to be
activated; IL-18 is associated to several inflammatory
disorders influencing both cellular and humoral immunity
[13–15]. The activity of IL-18 is balanced by the presence
of a high affinity, naturally occurring IL-18 binding pro-
tein (IL-18BP). In humans, increased disease severity can
be associated with an imbalance of IL-18 to IL-18BP such
that the levels of free IL-18 are elevated in the circulation
[15]. IL-18 synthesis was demonstrated in different brain
regions, mainly at the level of activated microglia; more-
over, IL-18 was shown to be increased in the brains of AD
patients [16], and in addition, IL-18 was shown to increase
amyloid-β production by human neuron-like cells [17]
affecting amyloid precursor protein (APP) processing and
therefore, Aβ production [18]. Finally, it is know that
autism patients exhibit increased amounts of APP in their
brain [19].
The aim of the present work is to evaluate IL-18 serum
levels in autism patients compared to healthy controls and
in the murine experimental model of autism, the Reeler
mice, compared to wild-type controls. Furthermore, we
investigated the expression of IL-18 in the brain sections
obtained from individuals affected by tuberous sclerosis
with autistic behavior, mimicking different features of
ASD subjects or by inflammatory diseases, compared to
normal subjects. IL-18 brain expression was investigated
in Reeler and wild-type mice as well.
Methods
Autism patients
Twenty-nine patients aged 2–21 including 27 males
were recruited for this study at the Center for Autism of
Hospital of Chiaromonte/Lagonegro (Potenza) and at the
Pediatrics Neuropsychiatry Department of Matera: two
Italian regional centers that coordinate services for per-
sons with autism which they were recruited from. Individ-
ual clinical characteristics of the 29 patients included in
the study are shown in Table 1. All patients present devel-
opmental records documenting characteristics and behav-
iors that met a standardized definition for American
Psychiatric Association (ASD; DSM-IV-TR 2000). Nine-
teen autistic patients were classified as severe, based
on a Childhood Autism Rating Scale (CARS) score of
37 or more; three patients were classified with mild-
to-moderate disease, as determined by CARS score be-
tween 32 and 37; and eight patients were classified as
mild, according to CARS score below 32. Twenty-nine
healthy age- and gender-matched subjects with no overt
neurological or psychiatric abnormalities were selected as
the control group.
Anamnestic medical social questionnaire
The questionnaire, conceived and developed by the Op-
erative and Research Unit of Social Medicine (University
“Sapienza” of Rome) identifying any phenotypic diversity
in autism spectrum, was administrated to the families of
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Table 1 Clinical characteristics of the 29 ASD patients
Patient Gender Delivery Babbling
(months)
Age first steps
(months)
CARS
score
Severity DSM-IV
diagnosis
Comorbidities/other relevant
clinical data
Family history Autoimmune diseases
allergy
1. M Natural 9 16 36.5 Moderate Autistic
disorder
Cardiovascular diseases, diabetes,
hypertension, dyslipidemia
Dust (mother)
2. M Natural 12 12 56 Severe Autistic
disorder
Impulse dyscontrol disorder Tumors Food allergies (mother)
3. M Natural 7 20 37 Moderate Autistic
disorder
Inhalant allergens Diabetes, hypertension,
dyslipidemia, neuropsychiatric
diseases
Nickel (mother)
4. M Caesarean section 6/7 18 32 Mild-
moderate
Autistic
disorder
Specific phobia Cardiovascular diseases, diabetes,
hypertension, dyslipidemia,
tumors, neuropsychiatric diseases
5. M Natural 6 12 45 Severe Autistic
disorder
Allergy to Dermatophagoides Tumors Psoriasis (mother)
6. M Caesarean section 6 12 56.5 Severe Autistic
disorder
Severe language disorder
7. M Caesarean section 6 12 41 Severe Autistic
disorder
Food allergies Cardiovascular diseases, obesity,
diabetes, hypertension,
dyslipidemia, tumors,
neuropsychiatric diseases
Pollen (mother)
8. M Natural 6 24 41.5 Severe Autistic
disorder
Cardiovascular diseases,
hypertension, tumors
9. M Natural 6 Severe
hypothonia
40 Severe Autistic
disorder
Diabetes, tumors Psoriasis (mother)
10. F Caesarean section 7 24 38 Severe Autistic
disorder
Cardiovascular diseases, obesity,
hypertension
Takayasu’s arteritis
(mother)
11. M Adopted when
he was 2 years old
48 Severe Autistic
disorder
Fish and vegetables allergy Lactose intolerance
(mother)
12. M Natural childbirth 6 months 18 months 31 Mild D.P.S.
NOS
Intolerant to gluten Hypertension Lactose intolerance
(mother)
13. M Caesarean section 7/8 months 12 months 40.5 Severe Autistic
disorder
Cardiovascular diseases, obesity,
Hypertension
Psoriasis (mother)
14. M Natural 12 months 12 months 40 Severe Autistic
disorder
Obesity Celiac disease (mother)
15. M Natural 7 12 33 Moderate Asperger
disorder
Cardiovascular diseases, obesity,
hypertension, tumors
16. M Caesarean section,
Premature, Jaundice
6 14 30.5 Mild Autistic
disorder
Previous hydrocephalus Rheumatoid arthritis
(sister), duster (mother)
17. M Natural 30 months 24 48 Severe Autistic
disorder
Discrete obsessive conducted
and tendency toward aggression.
Cognitive disabilities.
Psychopharmacological treatment
Food (mother), drug
(father)
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Table 1 Clinical characteristics of the 29 ASD patients (Continued)
18. M Natural 30 months 20 38 Severe Autistic
disorder
Food and Drugs (mother
and father)
19. M Caesarean section 6 17 20 Mild Pervasive
disorder
NOS
Atopic dermatitis (brother)
20. M Natural 8/9 months 13 months 23.5 Mild Pervasive
disorder
NOS
Cardiovascular diseases, obesity,
diabetes, hypertension,
dyslipidemia
Celiac disease (grand
mother), type 1 diabetes
(grand mother)
21. M Caesarean section 30 months
and after
regression
13 52 Severe Autistic
disorder
Cardiovascular diseases, tumors Rheumatoid arthritis
(mother), psoriasis (uncle),
ragweed hay fever (aunt)
22. M Natural 12 followed
by regression
19 39.5 Severe Autistic
disorder
Mite allergy (father), type 1
diabetes (grandfather)
23. M Natural 6 months 13 months 24 Mild Pervasive
disorder
NOS
Cardiovascular diseases,
hypertension, tumors
No
24. M Caesarean section 6 13 25 Mild Asperger
disorder
Cardiovascular diseases,
hypertension, tumors
Oat grass: lactose
intolerant (patient), grass
allergy (mother, uncle)
25. M Caesarean section 12 months 18 months 39 Severe Pervasive
disorder
NOS
Dysgenetic pathology ndd;
epileptic syndrome
pharmacological treatment
No
26. M Natural Not reported 18 46 Severe Autistic
disorder
Epileptic syndrome
pharmacological treatment
Psoriasis (father), lactose
intolerance (mother)
27. M Caesarean section 6 20 51 Severe Pervasive
disorder
NOS
Probable dysgenetic pathology
ndd; reduced cognitive skills,
ongoing antiepileptic treatment
Cardiovascular diseases,
hypertension, dyslipidemia
No
28. F Natural 6 13 31 Mild Autistic
disorder
Cardiovascular diseases,
hypertension, tumors
Grass, mite allergies (father)
29. M Natural 15 months 20 months 49 Severe Autistic
disorder
Genetic pathology ndd;
moderate-to-severe cognitive
disorder
Cardiovascular diseases,
hypertension, neuropsychiatric
diseases
Nickel allergy (grandmother),
psoriasis (mother)
NOS not otherwise specified
ndd not defined diagnosis
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patients by the medical staff of the hospital of Chiaro-
monte/Lagonegro (Potenza) and of the Pediatrics Neuro-
psychiatry Department of Matera. It was composed of
four sections: (i) child’s data including age, weight, height,
residence, blood type, age of first diagnosis and the sever-
ity of the disease, the type of vaccination, the stages of
language development, the sleep patterns and age at
weaning, weaning, nutrition, food allergies, and intoler-
ance; (ii) parental data; (iii) the presence of allergies, food
allergies, autoimmune diseases and other diseases, type of
diet, working site and exposure to possible harmful fac-
tors, personal lifestyles, pregnancy and childbirth, previous
surgery and family history for major diseases (especially
for autoimmune diseases like rheumatoid arthritis, psoria-
sis, and Crohn’s disease); (iv) socioeconomic aspects, such
as the use of computers and mobile phones, services and
support provided by local health authorities, town coun-
cils, and social and family health associations. The in-
vestigation conforms to the principles outlined in the
Declaration of Helsinki. Informed consent was obtained
before enrollment.
Blood sample assays
Venous blood from each individual was collected and
stored at 4 °C overnight. Serum was obtained after cen-
trifuging at 1500 rpm for 10 min at RT, aliquoted, and
stored at −80 °C until use. All the children were medica-
tion free and in good physical health at time of blood
sample assays.
Human samples for immunohistochemistry
The cases included in this study were obtained from the
archives of the departments of neuropathology of the Aca-
demic Medical Center (AMC, University of Amsterdam)
and the University Medical Center in Utrecht (UMCU). A
total of five brain tissue specimens (cortical tubers) re-
moved from tuberous sclerosis (TSC) patients (age at
surgery 2, 3, 3, 7, 47 years; F/M 3/2) undergoing surgery
for intractable epilepsy were examined. Tissue was ob-
tained and used in accordance with the Declaration of
Helsinki and the AMC Research Code provided by the
Medical Ethics Committee and approved by the science
committee of the UMC Utrecht biobank subjects. In
three of the five cases, information concerning the pres-
ence of mild-to-severe autistic behavior was available.
Control cortex/white matter was obtained at autopsy from
five age- and gender-matched control patients without
history of neurological diseases. Furthermore, we also
used histologically normal hippocampus (n = 3) and speci-
mens from patients with hippocampal sclerosis (n = 3) and
from two viral encephalitis patients.
Single-label immunohistochemistry with Ab anti-IL-18
(cat no. PAB16177, Abnova; 1:20) was performed, using the
Power Vision kit (Immunologic, Duiven, The Netherlands)
and 3,3-diaminobenzidine as chromogen [20]; sections
were counterstained with hematoxylin.
Reeler mice
B6C3Fe heterozygous female and wild-type male mice,
originally purchased from Jackson Laboratories (USA)
were housed in (33 × 13 × 14 cm) Plexiglas boxes with
sawdust bedding and a metal top (two animals per cage).
Animals were provided with tap water and food pellets
(Mucedola, Settimo Milanese, Italy) ad libitum. Mice were
kept on a 12-h light/dark schedule (lights off at 06:30
a.m.), and RT was maintained at 21 ± 1 °C with a relative
humidity 60 ± 10 %. Mice genotype was determined from
tail samples at weaning using the PCR genotyping proto-
col previously described [21].
A total of 11 WT and 11 heterozygous Reeler mice were
used for the present study. All procedures were performed
according to European Communities guidelines (EC Coun-
cil Directives 86/609/EEC and 2010/63/EU) and Italian
national legislation on animal experimentation (Decreto
L.vo 116/92) and formally approved by the Italian Ministry
of Health.
At the age of 1 month, mice were sacrificed under
isoflurane anesthesia.
Blood was collected by heart puncture in a test tube
containing EDTA 2 g/dL and immediately centrifuged to
separate the plasma and then stored at −80 °C. Brains
were perfused with PBS, removed, and bisected on the
sagittal plane. The left hemisphere was fixed in 4 %
formaldehyde for the immunohistochemical assays; the
cortex from the right hemisphere was dissected and
stored at −80 °C for the bio-molecular assays.
Reeler brain immunohistochemical analysis
Mice brains were fixed overnight in 10 % neutral-buffered
formalin (prepared as follows: formaldehyde 37–40 %
100 ml/L; distilled water 900 ml/L; sodium phosphate,
monobasic 4.0 g/L; sodium phosphate, dibasic (anhydrous)
6.5 g/L; Sigma cat. HT50-1-1), dehydrated and embedded
in paraffin. Microtome sections (2 μm thick) were stained
with hematoxylin-eosin for histological evaluation.
Microtome sections were rehydrated and incubated for
15 min in 0.3 % H2O2-methanol to block endogenous per-
oxidases. After extensive washing in PBS, sections were
incubated with Ab anti-IL-18 (cat no. PAB16177, Abnova,
dilution 1:50), rewashed, and treated with a biotinylated
anti mouse antibody and peroxidase-labeled streptavidin
(Dako, Glostrup, Denmark). Sections were then incubated
with DAB and extensively washed. The specificity of the
reaction was assessed by incubating adjacent sections with
isotype-matched irrelevant antibodies, instead of the pri-
mary antibody. Images were obtained with a Nikon Ni-E
microscope (Nikon, Japan). Furthermore, the sections
were analyzed by a NIS program for image analysis
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(Nikon, Japan) to evaluate the intensity of the reaction in
different fields. Five different fields were evaluated from
each section and an average of 110 cells was counted for
each field.
Western blotting
Brain tissues were isolated and homogenized in lysis
buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1 %
NP-40, 0.1 % SDS) and a mix of phosphatases and prote-
ases inhibitors (Complete Mini, Roche) using an Ultra-
Turrax homogenizer at 4 °C. Lysates were sonicated and
then clarified by centrifugation for 15 min at 10.000 g.
Protein concentration was determined using bovine serum
albumin (BSA) as a standard in a Bradford reagent assay
(Bio-Rad). Total lysates were boiled in SDS sample buffer,
separated by SDS-PAGE electrophoresis, and blotted to
nitrocellulose, membrane (Bio-Rad). Nitrocellulose mem-
branes were blocked in PBS-Tween-20 (0.1 %) plus 5 %
non-fat milk (Fluka) and incubated with anti IL-18 (1:200,
cat. PAB16177 Abnova), anti IL-18BP rabbit policlonal
(1:250, cat. bs-4040R, Bioss), or mouse monoclonal anti β-
actin (1:1000, cod. sc-81178, Santa Cruz Biotech) primary
antibodies for 16 h at +4 °C. After washing three times
with PBS-Tween, filters were incubated with peroxidase-
conjugated secondary antibodies (anti-mouse or rabbit
IgG; 1:4000; Amersham) for 1 h at RT. Detection was per-
formed by Enhanced Chemiluminescence kit (EuroClone).
For quantitative measurements, Western blot signals were
acquired and analyzed by a Fluor-S densitometer and the
Quantity One software (Bio-Rad); optical densities (OD)
from at least three different experiments were calculated
for each sample and normalized with the corresponding
β-actin signal OD; the OD ratios were then compared and
expressed as the average fold increase, with one (wt con-
trol) as the control value. Optical density values of β-actin
appeared unaffected by genotype and treatment. Similar
results were also obtained with membranes hybridized
with pan 14, 3, 3, and β-tubulin antibodies (not-shown;
sc-1657 and sc-5274, respectively, both from Santa Cruz
Biotech).
Cytokine production
Levels of serum cytokines were determined by ELISA fol-
lowing the manufacturer’s instructions using the following
kits:
MBL cat 7620 Human IL-18 ELISA kit based on
sandwich ELISA sensitivity 120.5 pg/mL;
Immunological Sciences cat. IK-10144 Human
brain-derived neurotrophic factor (BDNF) ELISA kit
based on sandwich ELISA sensitivity 15 pg/ml;
MBL cat 7625 Mouse IL-18 ELISA Kit based on
sandwich ELISA sensitivity 25.0 pg/mL;
MyBioSource cat MBS2507231Mouse IL18BP
(interleukin 18 binding protein) ELISA kit based on
sandwich ELISA sensitivity 0.094 ng/mL.
Statistical analysis
Values are expressed as mean ± SD in the text and figures.
One-way ANOVA was computed, and Bonferroni’s post-
test was used to calculate any significant (p < 0.05) differ-
ence in this paper.
Results
Table 1 summarizes clinical characteristics of ASD pa-
tients included in the study, describing in detail their
intolerances and allergies, their language development, the
presence of delay in babbling, CARS score, comorbidities
and other relevant clinical data, and family history.
In the present study, focus was placed on the presence
of autoimmune disorder, since the other conditions are
present in almost comparable levels in the group of healthy
patients: maternal autoimmune diseases include psoriasis
(four mothers), rheumatoid arthritis, celiac disease, and
Fig. 1 IL-18 serum levels in autism patients and healthy controls. a Values observed in autism patients aged below 10 years were significantly
lower compared to those of age- and sex-matched healthy controls (p < 0.0013); b values observed in autism patients above the age of 10 years
were significantly lower compared to those of age- and sex-matched healthy controls (p < 0.002)
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Takayasu’s arteritis. In one child, we found paternal famil-
iarity for psoriasis. Another child’ sister suffers from
rheumatoid arthritis.
Figure 1 shows the analysis of IL-18 levels in the sera
of autism patients and in age- and sex-matched healthy
controls. We observed significant differences in the levels
of IL-18 present in the sera of autistic patients regardless
of age, compared to the values measured in the sera
of healthy individuals. Indeed, in patients aged below
10 years, the IL-18 stands at a mean value of 600 pg/mL
and goes down to 400 pg /mL in children above the age of
10. The lowest values were observed in patients with
severe autism (CARS ≥37).
In order to check whether a similar difference was
also present in the brain, we evaluated the expression
of IL-18 by immunohistochemistry in the brain sections
(Limbic regions/Frontotemporal cortex + tuber) obtained
from patients with encephalitis, tuberous sclerosis, or con-
trols. Tuberous sclerosis is a multi-system genetic disease
where 25 to 61 % of affected individuals meet the diagnos-
tic criteria for autism with an even higher proportion
showing features of a broader pervasive developmental
disorder. As shown in Fig. 2, IL-18 was localized within
reactive astrocytes in the hippocampus of patients with
medically intractable temporal lobe epilepsy as well as in
reactive astrocytes of patients with viral encephalitis and
Fig. 2 Human brain IL-18 immunoreactivity (IR). a–b Control white matter (Wm; a) and gray matter (Gm; b) showing the absence of detectable
labeling. c Cortical specimen of a patient with viral encephalitis (herpes simplex encephalitis) with strong IR in astrocytes (arrows in c and inset).
d, e Dentate gyrus (DG) of control (d) and hippocampal sclerosis (HS, e) showing increased expression in HS; inset in e shows positive astrocytes;
arrows); gcl granular cell layer, ml molecular layer. f–h TSC specimens (cortical tuber) showing IL-18-positive reactive astrocytes (arrows in f; Wm)
and giant cells (arrows in g and h). Microglia in (e, f). Sections are counterstained with hematoxylin. Scale bar in h, a–b: 80 μm; d–e: 160 μm;
f–h: 40 μm
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in reactive astrocytes and giant cells in cortical tubers of
TSC patients. No reaction (below detection level) or weak
positivity at the level of hippocampal astrocytes was
present in normal brains.
We then decided to analyze the expression of IL-18 in
the brain of Reeler mice, an experimental model of aut-
ism, characterized by a mutation within Reelin, a glyco-
protein of the extracellular matrix that plays a key role
in migration and positioning of neurons, thus bearing a
fundamental neurodevelopmental role in the laminar
and columnar organization of the cortex [22, 23]. When
levels of Reelin are reduced by 50 %, as in heterozygous
mice compared to wild-type ones, several subtle neuro-
anatomical and behavioral abnormalities are detectable
[20]. We studied the presence of IL-18 and IL-18BP in
the brain of heterozygous Reeler mice as well as in wild
type: results are shown in Figs. 3 and 4 and in Table 2.
Several neurons of Reeler heterozygous mice brain were
stained, as well as astrocytes, microglia, and giant cells,
as shown in Figs. 3 and 4. We quantified the reaction by
gray density analysis obtained by NIS-Element AR pro-
gram and by counting positive cells in five different fields/
sections. Reeler brain sections resulted to have higher IL-
18 as well as IL-18BP associated positivity (the intensity of
the reaction was 10 % bigger; the number of positive cells
was tripled for IL-18 and more than doubled for IL-18BP
compared to wild-type brain sections). Moreover, we
analyzed the presence of IL-18 and IL-18BP in brain
homogenates by Western blots. As shown in Fig. 5, immu-
noblots revealed increased expression of both IL-18 and
IL-18BP in the brain of Reeler heterozygous mice com-
pared to wild type. In addition, we measured IL-18 and
IL-18 BP levels by ELISA in plasma of both mice strains.
The data indicated that IL-18 is reduced in Reeler mice
compared to wild type (p = 00.0556), whereas there was
not a significant difference in the IL-18BP plasma levels
from Reeler or wild-type mice (Fig. 6).
Finally, we analyzed BDNF levels in the sera from aut-
ism patient cohort. We grouped the patients according
to the severity of autism, and as shown in Fig. 7, all three
patient groups showed significantly higher levels of BDNF
compared to the healthy control group (t > 3.34, p < 0.01),
with higher amounts detected in patients with severe
autism (CARS ≥37): severe autism mean = 1170 pg/ml;
standard deviation = 372.7; healthy control sample means =
460.4 pg/mL; and standard deviation = 146.78. Patients
with severe autism showed IL-18 serum levels lower than
the other groups of patients and much lower than the
healthy controls: severe autism mean 113.17 pg/mL; stand-
ard deviation 23.79; healthy controls mean 529.9 pg/mL;
standard deviation = 274.1 (Figs. 1 and 7). Therefore, pa-
tients with severe autism (CARS ≥37) show low levels of
IL-18 but high levels of BDNF.
Discussion
Cytokine imbalance was claimed to impact neural activ-
ity and mediates behavioral aspects of autism spectrum
disorders [24]. ASD is very heterogeneous from a clinical
point of view and is equally very heterogeneous on the
genetic aspect [25], although a large number of genetic
variants associated with ASD converge toward a core set
of dysregulated biological processes involving abnormal
immune responses. Gene expression studies support the
concept that immune and inflammatory genes are up-
regulated in ASD, a phenomenon observed both in the
brain and in peripheral tissues [26]. Furthermore, it is
now established that cells belonging to the immune sys-
tem, such as microglia, are critical to maintaining normal
synaptic plasticity and that alterations of these cells
may have an impact on neuronal functions [27], and
Fig. 3 Immunolocalization of IL-18 and IL-18BP in the mice brain. Wild-type mice: IL-18-associated positivity. Neurons as well as astrocytes and
microglia are stained. a Magnification 4×; b magnification 10×; c magnification 20×; IL-18BP-associated positivity IL-18. d Magnification 10×;
e magnification 20×. Reeler mice: much neurons and glial cells are stained, and the reaction is stronger. IL-18-associated positivity. f Magnification
4×; g magnification 10×; h magnification 20×; IL-18BP-associated positivity. i Magnification 10×; l magnification 20×
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in particular, the cytokines produced by activated micro-
glia have been demonstrated to affect neuronal synaptic
function [28]. Previous results showed that neuroinflam-
mation, with increased amounts of IL-1β, IL-6, and TNF-
α, takes place in the brains of ASD subjects [29]. We have
shown in a previous study that altered levels of IL-1β, IL-
6, IL-12, TNF-α, IL-23, and BDNF occur in the sera of
autistic patients [9]. The present results indicate that there
is also a dysregulation of IL-18 levels, both in the serum
obtained from the same group of patients previously
under study as well as in brains of TSC affected subjects
with an inverse relationship, though, as a matter of fact,
we observed IL-18 decrease in the serum and increase in
the brain of both ASD patients and mouse model. The
largest decrease was detected in the sera of patients with
severe autism (CARS ≥37). It is not easy to explain why
quantitatively different levels have been found in the brain
compared to the sera of individuals with autism. Previous
studies reported that plasma levels of IL-18 were sig-
nificantly elevated in Alzheimer’s disease compared to
healthy controls, but that also levels of IL-18 transcript
and proteins were increased in frontal lobe of AD pa-
tients compared to healthy age-matched controls [16],
even if AD-severe patients showed low levels compared to
AD-mild patients [30]. El-Ansary and coworkers reported
that autistic children exhibited significantly lower serum
concentrations of both Aβ (1–40) and Aβ (1–42) com-
pared to control subjects, despite the higher amounts of
Aβ found in the brain of the subjects with autism [31].
Moreover, they detected unexpected lower concentrations
of caspase-3, TNF-α, and IL-6 in plasma of autistic pa-
tients compared to age- and gender-matching controls
[32] despite being known from other studies that the same
cytokines were increased in the brain of autistic subjects
[33]. The gene encoding for IL-18 and its receptor have
distinct promoter regions and then alternatively spliced
transcripts giving to these molecules the potential to be
produced in tissue-/cell-specific way in response to differ-
ent stimuli [34, 35]. Furthermore, the splice variants of
IL-18Rβ chain have been proposed to be the soluble
negative regulator of IL-18 action [36, 37].
IL-18 is physiologically produced in different regions
of the brain, including the hippocampus, the hypothal-
amus, and the cerebral cortex, where several isoforms of
its receptor have been identified [13]. It has been hy-
pothesized that IL-18 may have a role in central nervous
system development and is involved in synaptic plasticity,
in glutamate release and enhanced postsynaptic α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) re-
ceptor responses as well as in fear memory and spatial
learning [13, 38]. IL-18 is also induced during physical/
emotional stress responses [34, 39] and high levels of IL-18
are detected in several neuropathological conditions such
as during microbial infections, following trauma, stroke, or
ischemia. Our results, showing higher number of IL-18-
Fig. 4 Immunolocalization of IL-18 in the mice brain. Negative control a (20×), e (40×). The reaction associated to astrocytes and microglia within
wild-type brain (b, c, d) and astrocytes and microglia as well as neural cells within Reeler brain (f, g, h). The h inset depicts positive astrocytes. The
positivity was stronger and was detected in higher number of cells within the Reeler brain (b 10×, c 20×, d 40×, f 10×, g 20×, h 40×). Calibration
bar 50 μm
Table 2 IL-18- and IL-18BP-positive cells in the brain sections
Mice IL-18-positive
cells/total
cell number
IL-18-positive
cells (%)
IL-18BP-positive
cells/total cell
number
IL-18BP-positive
cells (%)
Wild type 1399/6040 23.16a 1477/5905 25.01a
Reeler 3417/5655 60.42 4407/6377 69.11
aFive different fields were analyzed for each sample (22 samples). In every
field, an average of 110 cells was counted p < 0.0001
Businaro et al. Journal of Neuroinflammation  (2016) 13:2 Page 9 of 13
positive cells in the brain of viral encephalitis patients
confirm these results. In addition, intrathecal injection of
IL-18 is able to induce behavioral, morphological, and bio-
chemical changes similar to that detected after nerve injury
[40]. Human IL-18 serum levels are elevated in patients
with multiple sclerosis [41], Alzheimer’s disease, vascular
dementia, and mild cognitive impairment [42]. Previous
studies suggested that brain high levels of IL-18 may
induce motor and cognitive dysfunctions, impairing learn-
ing and memory by acting as an attenuator of long-term
potentiation [40, 43]. Our finding is in agreement with pre-
vious results detecting increased levels of IL-18 in the brain
of an autism experimental mouse model consisting of an
inbred strain with behavioral deficits similar to those found
in children with autism [44].
In addition, IL-18 can enhance the production of toxic
inflammatory molecules such as interferon (IFN)-γ and
IL-1β [45, 46], and recent experimental and clinical
studies have proven the close connection between the
rise of pro-inflammatory cytokines, glucocorticoids, and
behavioral changes, such as those associated with anxiety
and depression [47, 48]. In this connection, the pro-
inflammatory cytokines induce an altered serotonergic
function by increasing the conversion of tryptophan to
kynurenine. The decrease in the synthesis of serotonin
in the brain leads to the formation of neurotoxins such
as quinolinic acid and N-methyl-D-aspartate (NMDA)
receptor agonist and contributes to increasing apoptotic
events in astrocytes, oligodendrocytes, and neurons, ex-
acerbating mood and oxidant status [49]. The diminished
serotonin content in the brain of autistic patients was
already revealed by positron emission tomography neuro-
imaging using a serotonin precursor [50] and was related
to language and sensory dysfunctions observed in autism
[51] as confirmed by the worsening of stereotyped move-
ments observed in autistic children following acute trypto-
phan depletion and subsequent reduction of serotonin
[52]. In fact, it was suggested that autism might be a
Fig. 5 IL-18 and IL-18BP detected by ELISA in the plasma of wild-type and Reeler mice (values expressed as mean ± SD). a IL-18 concentrations
(pg/mL) and b IL-18BP concentrations (ng/mL) in Reeler mice versus wild-type group. Plasma IL-18 was reduced in Reeler mice (p = 00.0556). No
significant difference was detected in IL-18BP levels in Reeler compared to wild-type mice
Fig. 6 IL-18 and IL-18BP Western blots of mice brain homogenates.
Representative Western blot analysis (summarized view corresponding
to four animals per group) of IL-18, IL-18BP, and β-actin proteins in
cortices of WT and Reeler mice. Bottom: semi-quantitative densitometric
analysis, obtained by optical density (OD) of IL-18 (left) and IL-18BP (right)
normalized with OD of β-actin bands; N= 11, p < 0.01
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disorder of serotonin metabolism. Pro-inflammatory cyto-
kines, including IFN-β and IFN-γ, have been shown to
reduce the availability of tryptophan, which is required
for 5-hydroxytryptamine synthesis through activation of
indoleamine-2,3-dioxygenase (IDO), an initiator of kynur-
enine pathway. IL-18 can enhance production of toxic
inflammatory molecules such as IFN-γ [43] and IL-1β
[46],which may lead to a vicious cycle where inflammatory
processes contribute to different aspects of neurodegener-
ation. Furthermore, IL-18 belongs to the family of pro-
inflammatory cytokines IL-1 and determines an activation
signal on neurons and glia increasing both the synaptic
release of glutamate and the expression of its postsynaptic
AMPA receptor. IL-1β inhibits the removal of glutamate
by astrocytes thus causing an excess of this excitatory
neurotransmitter that causes neurotoxicity [53].
Further studies are needed to clarify the cause that led
to the increase of IL-18 in the brain of patients with
autism and its downregulation in sera. We are aware
that the number of subjects analyzed is quite small due
to the difficulties of collecting samples from autistic chil-
dren, especially for the postmortem tissues from autistic
patients; however, our data represent the first attempt to
investigate the role of IL-18 in ASD, and the small sample
size seem appropriate for the exploratory aim of this work.
Furthermore, increasing the number of cases examined
will clarify whether the decrease of IL-18 in sera can be
considered a biomarker of the disease and if this measure
in combination with other markers, for example, increased
levels of BDNF may be included in a diagnostic panel. In
addition, the evaluation of SNPs at the level of IL-18 gene
or the existence of splice variants for the beta chain of IL-
18 receptor proposed to be the soluble negative regulator
of IL-18 action may give important information for the
better understanding of the mechanisms underlying IL-18
dysregulation.
Fig. 7 IL-18 and BDNF concentrations (pg/ml) in the sera of autism patients. Autistic patients were classified as severe, based on a Childhood
Autism Rating Scale (CARS) score of 37 or more; mild-to-moderate disease as determined by CARS score between 32 and 37; and mild, according
to CARS score below 32. An inverse relationship between IL-18 and BDNF was observed in the group of patients with severe autism
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Conclusions
Immune dysfunction is present in autism patients. IL-18
is reduced in sera but increased in the brain of patients
with tuberous sclerosis with autism. An IL-18 increase
was detected also in Reeler brains, mainly at the level of
neurons and glial cells; the higher amount of IL-18 was
paralleled by a quite similar increase in the amount of
IL-18BP. On the contrary, reduced levels of IL-18 were
measured in plasma of Reeler mice compared to wild-
type mice, whereas no significant variation of IL-18BP
was observed. Our data suggest that a chronic neuroin-
flammation is present in autism affected subjects, includ-
ing IL-18 dysregulation. The present study might open
new scenarios for the comprehension of molecular path-
ways of the disease.
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